Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.
| Revenue (TTM) | $1.28B |
| Gross Profit (TTM) | $1.17B |
| EBITDA | $-321.10M |
| Operating Margin | -15.50% |
| Return on Equity | -53.30% |
| Return on Assets | -17.80% |
| Revenue/Share (TTM) | $56.15 |
| Book Value | $22.68 |
| Price-to-Book | 22.39 |
| Price-to-Sales (TTM) | 9.13 |
| EV/Revenue | 8.75 |
| EV/EBITDA | -8.32 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 71.20% |
| Shares Outstanding | $23.10M |
| Float | $13.90M |
| % Insiders | 5.87% |
| % Institutions | 104.42% |
Volatility is currently contracting
CONSHOHOCKEN, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced it has appointed John C.
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
CONSHOHOCKEN, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that the company will participate in the Canaccord Genuity 46th Annual Growth Conference on Tuesday, Aug. 11, 2026 at 12:00 P.M. EDT.
Madrigal beats Q2 estimates as Rezdiffra sales lift revenues 71% year over year, but shares fall as investors weigh slower commercial growth.
Madrigal Pharmaceuticals NASDAQ: MDGL reported second-quarter 2026 net sales of $364.3 million for Rezdiffra, up 71% from a year earlier, as the company continued to expand the number of patients receiving its treatment for metabolic dysfunction-associated steatohepatitis, or MASH.
Madrigal Pharmaceuticals, Inc. (MDGL) Q2 2026 Earnings Call Transcript
Madrigal (MDGL) came out with a quarterly loss of $1.99 per share versus the Zacks Consensus Estimate of a loss of $2.55. This compares to a loss of $1.9 per share a year ago.
CONSHOHOCKEN, Pa., July 30, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports second-quarter 2026 financial results and provides corporate updates.
CONSHOHOCKEN, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on July 15, 2026 to ten new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
CONSHOHOCKEN, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its second-quarter 2026 financial results on Thursday, July 30, 2026, prior to the open of the U.S. financial markets.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MDGL and any ticker you trade — then tracks every position and per-strategy win rate.
